Physician profile
Lenka Rychetsky
NPI 1043286024
$3,815.31
in general payments reported to CMS, 2019-2025
30 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $119 · 2022: $341 · 2023: $659 · 2024: $1,175 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $682.38 | 2019-2025 | Evenity, Repatha, Otezla |
| Treace Medical Concepts, INC. | $450.00 | 2024 | |
| Lilly USA, LLC | $376.43 | 2019-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $357.40 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $244.66 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $233.38 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $195.60 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $190.31 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.34 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $101.05 | 2019-2020 | |
| Pfizer INC. | $99.54 | 2019-2025 | |
| Abbvie INC. | $83.09 | 2023-2025 | Ubrelvy, Qulipta |
| Eisai INC. | $77.71 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $74.13 | 2022-2023 | Austedo Xr |
| Amarin Pharma, INC. | $63.70 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.31 | 2024-2025 | Veozah |
| Shire North American Group INC | $47.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.73 | 2019-2023 | Xifaxan, Trulance |
| Radius Health, INC. | $36.20 | 2019 | |
| Allergan, INC. | $31.88 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $31.48 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $27.93 | 2024 | Spravato |
| Alexion Pharmaceuticals, INC. | $25.34 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.94 | 2023 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $24.42 | 2019 | |
| Exact Sciences Corporation | $16.45 | 2024 | Cologuard Collection Kit |
| Valeritas, INC. | $15.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.39 | 2023 | Quviviq |
| Abbott Laboratories | $12.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenka Rychetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.